Rivaroxaban as effective as warfarin for diabetic patients with atrial fibrillation, study finds

Rivaroxaban may be an effective treatment option over warfarin for patients with atrial fibrillation (AF), regardless of diabetes status, research from the ROCKET-AF trial has revealed. The study analysed more than 5,000 patient records of people with diabetes mellitus. Analysing those treated with warfarin and rivaroxaban, it found no significant differences in stroke and systemic embolism rates, or in major bleeding and intracerebral haemorrhage. Similarly, there were no differences between patients who had diabetes and those that didn’t. The findings were published online in the American Heart Journal. Previous findings, reported by heartwire from Medscape, from ROCKET-AF showed that rivaroxaban